Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals shareholding disclosures
72 filed, newest first. Page 2 of 2.
Sep 2013
25 Sep · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on September 24, 2013 allotted 4,600 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Aug 2013
19 Aug · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on August 17, 2013 allotted 61,300 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Jul 2013
18 Jul · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on July 18, 2013 allotted 21,800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Jun 2013
May 2013
27 May · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on May 27, 2013 allotted 9,400 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Apr 2013
17 Apr · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on April 17, 2013 allotted 42800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Feb 2013
15 Feb · Disclosure
Operations Committee of the Board of Directors of the Company, at its meeting held on February 15, 2013 allotted 47,200 shares to the employees of the Company on exercise of optios granted to them pursuant to ESOS 2003.
May 2012
8 May · Disclosure
Compensation Committee of the Company at its meeting held on May 07, 2012 has cancelled 2,01,500 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company.
Dec 2011
12 Dec · Disclosure
Compensation Committee of the Company, at its meeting held on December 07, 2011 has issued 25,000 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches.
Apr 2011
1 Apr · Disclosure
Compensation Commitee of the Company at its meeting held on March 30, 2011 has cancelled 408500 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company. Futher the Compensation Committee has issued 116000 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re. 1/- each in one or more tranches.
Oct 2010
1 Oct · Disclosure
At the Compensation Committee held on September 24, 2010 has allotted 1,11,000 stock options to the permanent employees pursuant to ESOS 2003.
Jun 2010
4 Jun · Disclosure
Board of Directors of the Company, at its Operations Committee Meeting held today i.e. on June 04, 2010 allotted 27,800 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Apr 2010
22 Apr · Disclosure
At the meeting of the Operations Committee of directors held on April 22, 2010 the Board has approved the conversion of 20,400 stock options issued to its employees into 20,400 Equity Shares pursuant to the ESOS 2003.
Jan 2010
29 Jan · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that at the Compensation Committee held on January 29, 2010 the Committee has cancelled 377,100 Stock options issued to the permanent employees pursuant to ESOS 2003.
Jul 2009
21 Jul · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "At the Compensation Committee held on July 14, 2009 the Committee has issue 141,500 stock options to the permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches and Cancelled 224,000 stock options".
Feb 2009
9 Feb · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Promoters / Promoter Group of the Company have not pledged any of their shares held in the Company. The report under Regulations 8A (4) shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
9 Sep · Disclosure
HSBC Global Asset Management (Hong Kong) Limited, on behalf of HSBC Global Asset Management (Singapore) Limited has informed the Exchange that HSBC Global Investment Funds a/c HSBC Global Investment Funds (Mauritius) Limited (the "Fund") managed by HSBC Global Asset Management (Singapore) Limited being the investment adviser of the Fund, currently hold 4.709% of the paid up share capital or voting capital of Glenmark Pharmaceuticals Ltd. Further, the Company has submitted to the Exchange a copy of the disclosure under the SEBI (Substantial Acquisition of Shares and Take-overs) Regulations. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
14 Jul · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Compensation Committee of the Company at its meeting held on July 09, 2008 has cancelled 2,82,500 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company. Further, the Compensation Committee has issued 1,93,000 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re. 1/- each in one or more tranches.
Dec 2007
12 Dec · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Compensation Committee of the Company, at its meeting held on 4th December, 2007 has issued 4,54,000 stock options to the employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches. The Compensation Committee of the Company, at its meeting held on 4th December, 2007 has cancelled 34,000 stock options (adjusted after issue of bonus equity shares in the ratio of 1:1 and split of the face value from Rs.2/- to Re.1/- per share) stock options issued pursuant to ESOS 2003, owing to employees leaving the services of the Company".